Hormone Replacement Therapy Patches Safer Than Oral Delivery for Women With Diabetes
FRIDAY, Sept. 19, 2025 -- Hormone replacement therapy (HRT) patches carry lower cardiovascular risk than oral HRT among women with type 2 diabetes, according to a study presented at the annual meeting of the European Association for the Study of Diabetes, held from Sept. 15 to 19 in Vienna.
Matthew Anson, from University of Liverpool in the United Kingdom, and colleagues used TriNetX electronic health record data to understand cardiovascular risk and gynecological- and estrogen-related cancers among women with type 2 diabetes using and not using HRT in midlife. The analysis included data from three cohorts composed of 24,986 patients.
The researchers found that in cohort 1, compared with HRT users without diabetes, transdermal HRT in women with diabetes was associated with a greater risk for deep vein thrombosis (hazard ratio [HR], 1.90; P = 0.002), ischemic heart disease (HR, 1.77; P < 0.001), and cerebral infarction (HR, 1.89; P < 0.001). There were no differences in rates of pulmonary embolism and breast, ovarian, or endometrial carcinoma. In cohort 2, among individuals with diabetes, use of transdermal HRT was associated with only a reduced risk for ischemic heart disease (HR, 0.75; P < 0.001) compared with nonusers. In cohort , among individuals with diabetes, use of oral versus transdermal HRT was associated with an increased risk for ischemic heart disease (HR, 1.21; P = 0.004) and pulmonary embolism (HR, 2.01; P < 0.001), but with no differences in risk for the other outcomes.
“Our study suggests that up to five years of regulator-approved doses of transdermal HRT appears safe in a large cohort of women in midlife with type 2 diabetes,” Anson said in a statement. “However, given increased risks with oral HRT, we propose that women with type 2 diabetes should not be prescribed oral estrogen therapy.”
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Metabolic Surgery Has Greater Long-Term Benefits Than GLP-1 Receptor Agonists
WEDNESDAY, Oct. 1, 2025 -- People with obesity and type 2 diabetes who undergo metabolic surgery live longer and face fewer serious health problems compared with patients treated...
GLP-1 Receptor Agonists Tied to Reduced Mortality in Patients With Psoriasis
TUESDAY, Sept. 30, 2025 -- Patients with psoriasis treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have better long-term outcomes compared with those taking...
Diabetes Tied to Doubled Risk for Sepsis
FRIDAY, Sept. 26, 2025 -- People living with type 2 diabetes experience double the risk for incident sepsis versus matched individuals without diabetes, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.